Kornimate/medical-research-clean huggingface dataset:
pelvic ring fractures: new analysis method and treatment decision algorithm

Conditions: Pelvic Fracture

Summary: pelvic ring fractures are common and often the result of high energy trauma but also sometimes of lower energy trauma in older patients. a good classification and description of the fracture is essential to the choice of treatment. the classifications used to describe these fractures are numerous (tile modified ao, young and burgess, letournel, rommens) and of a descriptive order more or less depending on the lesion mechanism allowing some to orient the surgical reduction technique. however, none of them helps with the choice of surgical or functional treatment, which is currently based on obvious notions of instability and / or displacement of lesions and, by habit, all different services. in addition, the complexity of these classifications leads to poor reproducibility of these. a new method for analyzing unitary lesions has been developed in the orthopedic surgery department of the paris saint-joseph hospital group with a rating system which determines the indication according to the score. teaching this new method of analyzing pelvic ring fractures would simplify decision making between surgical and functional treatment.


Eligibility criteria:
inclusion criteria: * patient aged\> 18 years * patient treated or followed within the orthopedic surgery service of the ghpsj for a pelvic ring fracture * complete initial imaging patient record (scanner) * french speaking patient exclusion criteria: * patients under guardianship or curatorship * patients deprived of their liberty * patients objecting to the use of their data for this research * patient with isolated sacral or acetabular fracture * absence of scanner during the initial assessment
safety and efficacy evaluation of topical al-60371 otic suspension, 0.3% in the treatment of acute otitis externa

Conditions: Acute Otitis Externa

Summary: the purpose of this study was to demonstrate the superiority of al-60371, 0.3% otic suspension relative to al-60371 vehicle based on clinical cures at test-of-cure (toc) for the treatment of acute otitis externa (aoe).

patients were evaluated for safety and efficacy during the visits conducted at day 3 (on-therapy), day 8 (end-of-therapy), and day 11 (toc). patients or parents/legal guardians completed a telephone diary twice daily to record assessments of ear pain, ear pain medication use, and the impact of ear pain on sleep and other daily activities.

Eligibility criteria:
inclusion criteria: * at least 6 months of age. * clinical diagnosis of acute otitis externa (aoe) based on clinical observation and of presumed bacterial origin in at least one ear. * combined numerical score of ≥4 in at least one affected ear at the day 1 exam for tenderness, erythema, and edema. * agree to refrain from water immersion of the ears during the conduct of the entire study. * other protocol-defined inclusion criteria may apply. exclusion criteria: * duration of signs or symptoms of aoe greater than 28 days in the affected ear(s) as reported by patient or parent/guardian. * presence of a tympanostomy tube or perforated tympanic membrane in the affected ear(s). * clinically diagnosed otic disease other than aoe (eg, malignant otitis externa) in the affected ear(s). * known or suspected ear infection of yeast, fungal or mycobacterial origin in the affected ear(s). * prior otologic surgery within 6 months of study entry in the affected ear(s). * known or suspected allergy or hypersensitivity to quinolones or other ingredients present in the medications to be used in the study. * patients who use ear plugs, head phones or ear buds and are unwilling to discontinue their use during the study period. * other protocol-defined exclusion criteria may apply.

Keywords: acute otitis externa
effectiveness of bariatric surgery for nafld/nash

Conditions: Bariatric Surgery Candidate; NAFLD; NASH With Fibrosis

Summary: this is a prospective, multicenter cohort study, which subjects were obese patients requiring bariatric surgery. this study aims to explore the the effectiveness of bariatric surgery for nafld/nash with fribrosis, to explore the differences in the effectiveness among sleeve gastrostomy \[sg\], roux-en-y gastric bypass \[rygb\], or one anastomosis gastric bypass \[oagb\], and to explore the independent effectiveness of bariatric surgery in histological remission of nafld/nash. the first stage of the cohort was started in 2020, named base-nafld; in may 2024, based on base-nafld, we plan to continue established a secondary cohort, named base-nash.


Eligibility criteria:
inclusion criteria: \[for base-nafld\] 1. age between 16 and 65 years (all sexes). 2. diagnosed with obesity according to the world health organization criteria for obesity in asian populations and scheduled for a primary bariatric surgery at the participating centres. 3. diagnosed with hepatic steatosis preoperatively by radiologic (including ultrasonography, magnetic resonance imaging \[mri\]-derived proton density fat fraction \[pdff\]) or pathologic(intraoperative hepatic pathology) examinations. \[for base-nash\] 1. age between 16 and 65 years (all sexes). 2. diagnosed with obesity according to the world health organization criteria for obesity in asian populations and scheduled for a primary bariatric surgery at the participating centres. 3. histologically confirmed nash with fibrosis: nafld activity score(nas) ≥4 with at least 1 in each single item and nash-crn fibrosis stage ≥f1 exclusion criteria: * any patient who had previously been submitted to any type of bariatric surgery; * history of excessive drinking: in the past 12 months, the male equivalent of alcohol consumption more than 30g/d, and the female more than 20g/d; * history of taking amiodarone, methotrexate, tamoxifen, glucocorticoids, etc.； * history of specific diseases: gene type 3 hepatitis c virus (hcv) infection, hepatolenticular degeneration, autoimmune hepatitis, total parenteral nutrition, lack of beta lipoproteinemia, congenital lipid atrophy, celiac disease which causing fatty liver, etc.; * previous major gastrointestinal surgery； * diagnosed or suspected malignancy； * poorly controlled significant medical or psychiatric disorders； * disorders such as a medical history of major pathology; * can not be able to understand and willing to participate in this registry with signature.

Keywords: bariatric surgery nafld nash fibrosis obesity
comparison between handheld rebound tonometer and applanation tonometer in iop measurement in paediatric glaucomas

Conditions: Glaucoma

Summary: to compare the accuracy between handheld rebound tonometer \& applanation tonometer in iop measurement in pediatric glaucoma cases


Eligibility criteria:
inclusion criteria: * patients attending to our pediatric glaucoma clinic diagnosed with glaucoma aged \>18 years old are subjected to iop measurements. exclusion criteria: * \*\*patients aged more than 18 years old * patients with scarred cornea
effect of applying ujjayi pranayama on cortisol in lupus patients

Conditions: Systemic Lupus Erythematosus

Summary: stress vulnerability is very common in lupus patients, specifically women, hence the rates of depression , insomnia, easy fatigue perception, anxiety are high in those women. pranayama is a yogic intervention that may treat the above problems

lupus patients, specifically 40 women, will divided to group number 1 and group number 2. the women in every group will be 20 women. group number 1 will receive home-based ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised). the group number 2 will not receive ujjayi pranayama, so it serves as control lupus group

Eligibility criteria:
inclusion criteria: * 40 lupus women exclusion criteria: * lupus co-morbidities * illiteracy
efficacy of start (startle rehabilitation therapy) in the treatment stroke-induced aphasia/apraxia

Conditions: Stroke; Aphasia; Apraxia of Speech

Summary: a stratified, parallel-group, double-blind, randomized controlled trial of remotely delivered start treatment to individuals with severe-to-moderate stroke (with recruitment focused on individuals with low ses) will be conducted. subjects and assessors will be blinded to the condition making the experiment double blind. specifically, subjects will be told that we are exploring a new therapy that using different sounds to improve therapy. parallel group design will ensure that subjects in the control group are unaware that their "sounds" are softer than the start group. trainers may become aware that a loud sound is present thus a unique assessor will evaluate clinical performance before and after training making the study double-blind. fifty-four subjects will undergo baseline testing in the laboratory to establish their capacity for functional and expressive speech as well as their self-reported health-related quality of life (power analysis below). next, subjects will participate in a high-frequency, word-picture verification/ auditory-repetition treatment, 2 hr/day for 5 consecutive days focusing on expression of words of functional significance (e.g., water, fall). subjects will either receive training with start or without (control). subjects will be re-tested immediately following training as well as one-month post to assess retention. aim 1 will evaluate capacity of start to enhance slt outcomes by assessing the % change in clinical assessment of functional and expressive speech. our preliminary data points to a robust response \[details\]. aim 2 will focus on the capacity of these changes to 1) be retained and 2) impact subject's reported quality of life. note: while we are planning in-person baseline, end, and retention testing, in response to covid, we have established remote clinical screening using peer-reviewed validated techniques for wab and aba-2 (see alternative solutions). all preliminary data collected for this proposal were collected remotely via no-contact protocols.


Eligibility criteria:
inclusion criteria: * 18 years old * native english speakers * capacity to provide informed consent * right-handed * corrected to normal vision * left hemisphere cerebral stroke at least 6 months prior to testing * presence of severe-to-moderate, non-fluent aphasia, i.e. aphasia quotients of 0-50 on the western aphasia battery-revised (psychcorp, 2007) * corrected pure tone threshold (octave frequencies 250- 4000 hz) norms for their age and gender41,42 note: audiometry data will be collected for all participants by lab personnel trained by an audiologist in a sound-attenuated booth. based on our ongoing aphasia studies, we expect that \~30% of participants will use hearing aids; we will not exclude these individuals but rather include hearing aid use as a covariate in analyses. exclusion criteria: * severe concurrent uncontrolled medical problems (e.g. cardiorespiratory impairment).
valor: the talent thoracic stent graft system clinical study

Conditions: Thoracic Aortic Aneurysms

Summary: a descending thoracic aneurysm is a bulge in the aorta. the aorta is a large blood vessel that carries blood away from your heart to organs in the rest of your body. your aneurysm is caused by a weakening in the artery wall. if left untreated, this bulge may continue to grow larger and may ultimately rupture (break open) or extend in size to seriously affect other major arteries in the area. in this research study a device will be placed inside your aorta to block the weakened part of the artery wall from the circulatory system. information will be collected on the performance for the device for 5 years.


Eligibility criteria:
talent captivia inclusion criteria 1. patient is at least 18 years of age. 2. patient is a surgical or non-surgical candidate 3. patient has a: 1. fusiform focal taa and / or 2. focal saccular taa or penetrating atherosclerotic ulcer. 4. subject's anatomy must meet all of the following anatomical criteria: 1. iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories 2. non-aneurysmal aortic diameter in the range of 18-42mm; and 3. non-aneurysmal aortic proximal and distal neck lengths =/\>20mm 5. thoracic aortic lesion is confirmed, at a minimum, by diagnostic contrast enhanced computerized tomography (cta) with optional 3-d reconstruction, and/or contrast enhanced magnetic resonance angiogram (mra) obtained within the previous three (3) months prior to the implant procedure. 6. subject or subject's legal representative understands and has signed an informed consent approved by the sponsor and by the irb for this study. 7. patient must be able and willing to undergo follow-up imaging and examinations postoperatively up to 6 months. talent captivia exclusion criteria 1. planned placement of the covered (top edge of fabric) portion of the stent graft requires implant to occur in zones 0 or 1 2. pregnant female 3. patient has a connective tissue disease (e.g marfan's syndrome, medial degeneration). 4. patient has a mycotic aneurysm or is suspected of having systemic infection. 5. patient has a history of bleeding diathesis, coagulopathy, or refuses blood transfusions. 6. patient is currently participating in an investigational drug or device clinical trial that would interfere with the talent captivia protocol endpoints or follow-up. 7. the patient has known allergy or intolerance to the device components. 8. the patient has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment. 9. the patient has another medical condition, which may cause them to be non-compliant with the protocol, confound the data interpretation, or limited life expectancy of less than 6 months.
research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: the investigators are doing this study to see the effect of insulin degludec in pregnant women with type 1 diabetes, and if it is safe to use. in this study the medicine insulin degludec is compared to another medicine called insulin detemir. participants will either get insulin degludec or insulin detemir and take it together with a medicine called insulin aspart - which treatment participants get is decided by chance. participants will get pre-filled insulin pens. participants will need to take blood sugar measurements several times a day. the study will last between 10 and 25 months depending on whether participants are already pregnant when they join the study. the number of visits and the tests ( for example blood and urine samples and ultrasound scans) the participants will have also depends on whether they are pregnant at study start.


Eligibility criteria:
inclusion criteria: - female, age at least 18 years at the time of signing informed consent - diagnosed with type 1 diabetes mellitus for at least 1 year prior to the day of screening - treated with multiple daily subcutaneous insulin injections or continuous subcutaneous insulin infusion (csii) or inhaled insulin for at least 90 days prior to the day of screening - the subject is planning to become pregnant within 12 months from randomisation and willing to undertake pre-pregnancy counselling or the subject is pregnant with an intrauterine singleton living foetus (gestational week 8 to 13 (+6 days)) without any observed anomalies at randomisation, confirmed by an ultrasound scan - hba1c at screening below or equal to 8.0% (64 mmol/mol) by central laboratory exclusion criteria: - treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening - pregnant and having proteinuria as evaluated by urine protein-to-creatinine ratio above or equal to 300 mg/g in urine sample measured at screening - subject being treated or became pregnant with assistance of in vitro fertilisation or other medical infertility treatment - receipt of any concomitant medication contraindicated in pregnancy according to local label within 28 days before screening and between screening and randomisation for non-pregnant subjects and 28 days before conception and between conception and randomisation for pregnant subjects - proliferative retinopathy or maculopathy requiring acute treatment. verified by fundus photography or pharmacologically dilated fundoscopy performed within the past 90 days prior to randomisation for non-pregnant subjects or within 28 days prior to randomisation for pregnant subjects. - history of severe hyperemesis gravidarum (requiring hospitalisation)
radial artery versus saphenous vein patency (rsvp) study

Conditions: Coronary Arteriosclerosis

Summary: the purpose of this study is to determine whether the radial artery (artery in the arm) or saphenous vein (vein in the leg), when used as bypass grafts for coronary artery bypass surgery, have a greater patency rate (degree of opening)at 5 years after surgery.

arteries differ from veins both in morphology and physiology. thus the way they behave as in vivo conduits when used in coronary artery bypass grafting is also likely to be different. this may partly explain the predisposition of veins used as coronary conduits to accelerated atherosclerosis in comparison with the internal mammary artery grafts. there are presently few data describing the properties of the radial artery as an in-vivo coronary conduit over the longer-term. the study will compare angiographic patency of the radial artery or saphenous vein graft anastomosed to the native left circumflex coronary territory at 3 months and 5 years after surgery. a substudy will compare 5-year post-surgery diameter and blood flow of in-vivo radial artery and saphenous vein grafts in response to endothelium-dependent and non-endothelium-dependent stimuli when patients attend for their scheduled follow-up angiogram.

Eligibility criteria:
inclusion criteria: * on waiting list for clinically-indicated myocardial revascularization surgery * aged 40-70 years * significant stenosis (≥70%) in the circumflex territory as identified on preoperative angiograms * negative allen's test (defined as the return of palmar circulation within 5 seconds of releasing ulnar artery compression) * willing to give written informed consent exclusion criteria: * poor left ventricular (lv) function (lv ejection fraction \<25%) * severe diffuse peripheral vascular disease or bilateral varicose venous disease * inability to comply with the angiographic follow-up at 3 months or/and 5 years

Keywords: coronary artery bypass coronary arteries atherosclerosis angiography blood flow
prevalence of covid-19 in a french dependent care facility for the elderly and in a french long-term care unit: observational study

Conditions: Covid19

Summary: the aim of this study is to evaluate the prevalence of covid-19 among the residents and geriatric inpatients of the care facilities attached to the centre hospitalier sud essonne (a general hospital located in ile-de-france, france), and the factors that are likely to influence this prevalence.

among people exposed to the covid-19 (sars-cov-2) pandemic, elderly people are considered as particularly vulnerable, especially those living in nursing homes or hospitalized. furthermore, facilities / accommodations are registered among the main locations of covid-19 clusters. these observations have led the french government to establish specific protection measures and survey dependent care facilities for the elderly and long-term care units in the hospital. with these new standards established, a long-term study of all the residents and geriatric inpatients of the care facilities attached to the centre hospitalier sud essonne (a general hospital located in ile-de-france, france), can provide additional knowledge on covid-19.

Eligibility criteria:
inclusion criteria: * residents of the dependant care facility for the elderly * inpatients of the long-term care unit * from march, 2020 to december, 2021 exclusion criteria: * opposition to participate in this study

Keywords: elderly covid sars-cov-2 prevalence dependant care long-term unit
a research trial looking at the comparability of 2 different concentrations of semaglutide for the 0.5 milligram (mg) dose

Conditions: Diabetes Mellitus, Type 2; Healthy Participants

Summary: in this study, a known investigational medicine called 'semaglutide' will be tested in 2 drug concentrations of 0.68 milligram per milliliter (mg/ml) and 1.34 mg/ml. both drug concentrations are tested for the treatment of type 2 diabetes. the u.s. food and drug administration (fda), has approved semaglutide in prefilled pen-injector form. currently, the drug concentration of 1.34 mg/ml can be prescribed in some countries including u.s. the objective of the study is to compare the amount of investigational drug taken up in the body for the 2 drug concentrations. participants will be divided by chance into 2 groups. group a will receive a single dose of 0.5 mg semaglutide of the drug concentration 1.34 mg/ml in the first study period; and will receive a single dose of 0.5 mg semaglutide of the drug concentration 0.68 mg/ml in the second study period. participants assigned to group b will receive the two drug concentrations in the reverse order. participants will get 1 subcutaneous injection on day 1 of each of the two study periods. the two injections are separated by 7-11 weeks. the study will last up to approximately 87 to 141 days for each participant. this includes a screening period (up to 4 weeks), study period 1 (5 weeks), washout period (2-6 weeks), and study period 2 (5 weeks). at some periods during the study, participant should not get vaccinations. participant should agree on timing of vaccination with study doctor. women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.


Eligibility criteria:
inclusion criteria: * male or female * aged 18-55 years (both inclusive) at the time of signing informed consent * body mass index (bmi) between 20.0 and 29.9 kilograms per meter square (kg/m\^2) (both inclusive) exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method * any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol * use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medications, highly effective contraceptives and occasional use of paracetamol, ibuprofen and acetylsalicylic acid, within 14 days prior to the day of screening * abuse or intake of alcohol, defined as any of the below: 1. known or suspected alcohol abuse within 1 year before screening (defined as regular intake of more than an average intake of 24 grams (g) alcohol daily for men and 12 g alcohol daily for women - 12 g of alcohol equals about 300 milliliters (ml) of beer or lager, 100 ml of wine, or 25 ml spirits) 2. positive alcohol test at screening * abuse or intake of drugs, defined as any of the below: 1. known or suspected drug or chemical substance abuse within 1 year before screening 2. positive drug of abuse test at screening